2021-08-05

Stemedica Cell Technologies, Inc., a US company with investment from JZT, started recruiting patients for its Phase II COVID-19 study.

2021-02-25

Jiuzhitang Maker received fund support from Daxing District Program for Advancing Transfer and Transformation of Technological Achievements.

2021-01-12

China’s first clinical trial treating ischemic stroke with an imported stem cell product was formally launched.

2020-12-19

Jiuzhitang Maker was awarded the prize of "Excellent Enterprise Assuming Social Responsibilities in 2020" by Health News.

2020-12-18

Jiuzhitang Maker was officially recognized as a company qualified to establish a postdoctoral station.

2020-12-06

Jiuzhitang Maker participated in the 2nd Anti-Aging Conference of China at invitation.

2020-11-16

A team led by Wang Youguo, Deputy Party Chief and Governor of Daxing District, visited Jiuzhitang Maker.

2020-11-02

Jiuzhitang Maker was selected as one of the “Top 50 Most Innovative Biomedical Enterprises in China for 2020”.

2020-09-27

Stemedica Cell Technologies, Inc., a US company with investment from JZT, received US FDA approval of its application for a Phase II clinical trial treating COVID-19 patients with MSCs.

2020-09-11

A team led by Yang Tingshuang, Party Chief of Mudanjiang, Heilongjiang Province, visited Jiuzhitang Maker.

2020-07-28

Stemedica Cell Technologies, Inc., a US company with investment from JZT, reported remarkable benefits in a study using MSCs to treat 8 COVID-19 patients.

2020-07-06

Jiuzhitang Maker and Tiantan Hospital signed a Clinical Trial Cooperation Agreement.

2020-05-16

Jiuzhitang Maker was included into Daxing government development planning.

2020-05-14

A team led by Academician Wu Zuze, dubbed as Father of Hematopoietic Stem Cells, visited Jiuzhitang Maker.

2020-04-20

Stemedica Cell Technologies, Inc., a US company with investment from JZT, received US FDA emergency IND approval for using its bone marrow-derived mesenchymal stem cells to treat severe COVID-19 cases.

2020-04-02

Jiuzhitang Maker received fund support from Daxing District Program for Better Development of the Healthcare Industry.

2020-03-20

Jiuzhitang Maker was included in a government project translating results from COVID-19 prevention and treatment work.

2020-02-19

Jiuzhitang Maker’s Investigational New Drug application for MSC product was approved.

2020-01-14

Jiuzhitang Maker was awarded the title of “ZGC Gold Seed Enterprise”.

2019-12-24

Jiuzhitang Maker received fund support from Beijing Science and Technology Major Project initiative.

2019-12-18

all staff of Jiuzhitang Maker moved into the company’s newly constructed Daxing facility.

2019-11-21

Jiuzhitang Maker’s Investigational New Drug application for MSC product was accepted by Center for Drug Evaluation of NMPA.

2019-10-22

Jiuzhitang Maker was officially awarded the certificate of “National High-tech Enterprise”.

2019-09-07

Jiuzhitang-ALTACO International Healthcare Center held a grand opening ceremony in China-Kazakhstan Khorgos Frontier International Cooperation Center.

2019-05-30

Jiuzhitang Maker became a full enterprise member of Chinese Society for Cell Biology.

2019-02-25

Jiuzhitang Maker was officially awarded Certificate of Zhongguancun High Technology Enterprise.

2018-09-14

Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd. signed cooperation agreements with Mexican company Novastem and Kazakhstan company ALTACO respectively, in an effort to co-build internationalized stem cell research platforms.

2019-01-12

The M&A Fund initiated by Jiuzhitang achieved new progress in its investment efforts in the stem cells field – Stemedica Cell Technologies, Inc. of which the Fund has holding interests announced positive data from its clinical study on cerebral stroke.

2018-09-14

Press Conference of Jiuzhitang Qihang Fund’s Investment in Stemedica Cell Technologies, Inc. & Global Stem Cell Industry Development Summit was successfully held in Beijing.

2018-09-12

Stemedica mesenchymal stem cells were approved and listed by Ministry of Health of Kazakhstan as a treatment of acute myocardial infarction.